Are stem cell stocks worth it?

Investing in stem cell stocks often means putting money on companies that have yet to have products on the market. As a result, they have historically been high risk, fluctuating up and down as public sentiment changes. These make people wonder if these stem cell companies are worth it in the long run, but stem cell research looks very promising.

What are the top NASDAQ stem cell stocks?

AstraZeneca (NASDAQ:AZN) Market cap: US$207.4 billion First on this list of the top NASDAQ stem cell stocks is multinational pharma and biotech firm AstraZeneca, which also specializes in other therapeutic areas, including oncology, cardiovascular diseases, the respiratory and central nervous systems and pain control.

Are there any publicly traded stem cell stocks?

As you can see, there are nearly 40 publicly traded stem cell stocks for you to consider. 1. ADR-Autolus Therapeutics-NASDAQ Autolus Therapeutics focuses on T-cell therapies for cancer patients. 2. ALPMY-Astellas Pharma-NASDAQ Astellas is a biotech company dealing with cancer, specifically bladder cancer.